JP2010523670A5 - - Google Patents

Download PDF

Info

Publication number
JP2010523670A5
JP2010523670A5 JP2010503045A JP2010503045A JP2010523670A5 JP 2010523670 A5 JP2010523670 A5 JP 2010523670A5 JP 2010503045 A JP2010503045 A JP 2010503045A JP 2010503045 A JP2010503045 A JP 2010503045A JP 2010523670 A5 JP2010523670 A5 JP 2010523670A5
Authority
JP
Japan
Prior art keywords
cancer
medicament according
optionally substituted
alkyl
rapamycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010503045A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010523670A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/004573 external-priority patent/WO2008124161A1/en
Publication of JP2010523670A publication Critical patent/JP2010523670A/ja
Publication of JP2010523670A5 publication Critical patent/JP2010523670A5/ja
Pending legal-status Critical Current

Links

JP2010503045A 2007-04-10 2008-04-09 Pi3kアルファのピリドピリミジノン阻害剤を使用した治療方法 Pending JP2010523670A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92289907P 2007-04-10 2007-04-10
PCT/US2008/004573 WO2008124161A1 (en) 2007-04-10 2008-04-09 Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013194611A Division JP2014034576A (ja) 2007-04-10 2013-09-19 Pi3kアルファのピリドピリミジノン阻害剤を使用した治療方法

Publications (2)

Publication Number Publication Date
JP2010523670A JP2010523670A (ja) 2010-07-15
JP2010523670A5 true JP2010523670A5 (enExample) 2011-05-26

Family

ID=39627802

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010503045A Pending JP2010523670A (ja) 2007-04-10 2008-04-09 Pi3kアルファのピリドピリミジノン阻害剤を使用した治療方法
JP2013194611A Pending JP2014034576A (ja) 2007-04-10 2013-09-19 Pi3kアルファのピリドピリミジノン阻害剤を使用した治療方法
JP2014059561A Pending JP2014139217A (ja) 2007-04-10 2014-03-24 Pi3kアルファのピリドピリミジノン阻害剤を使用した治療方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013194611A Pending JP2014034576A (ja) 2007-04-10 2013-09-19 Pi3kアルファのピリドピリミジノン阻害剤を使用した治療方法
JP2014059561A Pending JP2014139217A (ja) 2007-04-10 2014-03-24 Pi3kアルファのピリドピリミジノン阻害剤を使用した治療方法

Country Status (31)

Country Link
US (1) US8513266B2 (enExample)
EP (1) EP2139484B9 (enExample)
JP (3) JP2010523670A (enExample)
KR (1) KR101626435B1 (enExample)
CN (2) CN101715345A (enExample)
AU (1) AU2008236562B2 (enExample)
BR (1) BRPI0810206A2 (enExample)
CA (1) CA2683641C (enExample)
CO (1) CO6251254A2 (enExample)
CR (1) CR11100A (enExample)
DK (1) DK2139484T3 (enExample)
DO (1) DOP2009000243A (enExample)
EA (1) EA020022B1 (enExample)
EC (1) ECSP099724A (enExample)
ES (1) ES2430614T3 (enExample)
HN (1) HN2009003002A (enExample)
HR (1) HRP20130688T1 (enExample)
IL (1) IL201284A (enExample)
MA (1) MA31358B1 (enExample)
ME (1) ME00936B (enExample)
MX (1) MX2009010930A (enExample)
MY (1) MY150697A (enExample)
NZ (1) NZ580110A (enExample)
PL (1) PL2139484T3 (enExample)
PT (1) PT2139484E (enExample)
RS (1) RS52939B (enExample)
SI (1) SI2139484T1 (enExample)
TN (1) TN2009000400A1 (enExample)
UA (1) UA100979C2 (enExample)
WO (1) WO2008124161A1 (enExample)
ZA (1) ZA200906764B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200726767A (en) * 2005-07-04 2007-07-16 Astrazeneca Ab Chemical compounds 2
ES2513165T3 (es) * 2005-10-07 2014-10-24 Exelixis, Inc. Derivados de N-(3-amino-quinoxalin-2-il)-sulfonamida y su uso como inhibidores de la fosfatidilinositol-3-quinasa
US8044062B2 (en) * 2005-10-07 2011-10-25 Exelixis, Inc. Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha
JP2010500994A (ja) 2006-08-16 2010-01-14 エグゼリクシス, インコーポレイテッド Pi3kおよびmekモジュレーターを使用する方法
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
SA08280783B1 (ar) * 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
UA100979C2 (ru) 2007-04-10 2013-02-25 Экселиксис, Инк. Применение пиридопиримидиноновых ингибиторов pi3k альфа для лечения рака
NZ580009A (en) * 2007-04-11 2012-06-29 Exelixis Inc Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
US8470834B2 (en) 2008-08-20 2013-06-25 Merck Sharp & Dohme Corp. AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734486A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
TW201020238A (en) * 2008-08-20 2010-06-01 Schering Corp Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AU2009282571B2 (en) 2008-08-20 2014-12-11 Merck Sharp & Dohme Corp. Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AR080151A1 (es) 2010-02-09 2012-03-14 Exelixis Inc Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia
US20130156768A1 (en) * 2010-08-26 2013-06-20 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseases
TWI642670B (zh) 2010-09-14 2018-12-01 伊塞利克斯公司 Pi3k-德爾塔抑制劑以及其應用和生產方法
WO2012065019A2 (en) 2010-11-12 2012-05-18 Exelixis, Inc. Pyridopyrimidinone inhibitors of p13k alpha
US9441013B2 (en) * 2011-05-17 2016-09-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanocortin 1 receptor ligands and methods of use
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法
RU2014107713A (ru) * 2011-07-28 2015-09-10 Дженентек, Инк Модель рака молочной железы у животных, кроме человека, с активируемым pik3ca h1047r
WO2013056067A1 (en) * 2011-10-13 2013-04-18 Exelixis, Inc. Compounds for use in the treatment of basal cell carcinoma
PE20141794A1 (es) 2011-11-01 2014-12-17 Exelixis Inc N-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilalaninamida como inhibidor de fosfatidilinositol 3-quinasa para el tratamiento de neoplasias linfoproliferativas
EP2776837A4 (en) * 2011-11-11 2015-05-20 Intellikine Llc COMBINATION OF KINASEINHIBITORS AND THEIR USE
EP2797628A4 (en) 2011-12-27 2015-07-29 Kadmon Corp Llc METHOD FOR THE TREATMENT OF BREAST CANCER NOT RELATED TO TRASTUZUMAB
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CA2880896C (en) 2012-06-26 2021-11-16 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
US8980259B2 (en) * 2012-07-20 2015-03-17 Novartis Ag Combination therapy
EP2882440B1 (en) 2012-08-07 2019-02-27 Novartis AG Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
KR20220110859A (ko) 2016-03-04 2022-08-09 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
JP6563623B1 (ja) * 2016-08-15 2019-08-21 ファイザー・インク ピリドピリミジノンcdk2/4/6阻害剤
JP7027699B2 (ja) * 2017-05-09 2022-03-02 住友ゴム工業株式会社 タイヤトレッドおよびタイヤ
EA202091763A1 (ru) 2018-01-31 2020-12-14 ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Комбинированная терапия для лечения мастоцитоза
SG11202007198WA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of gastrointestinal stromal tumors
MX2020009762A (es) 2018-03-19 2021-01-08 Taiho Pharmaceutical Co Ltd Composicion farmaceutica que incluye alquil sulfato de sodio.
EP3938363A1 (en) 2019-03-11 2022-01-19 Teva Pharmaceuticals International GmbH Solid state forms of ripretinib
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
JP7818502B2 (ja) 2019-08-12 2026-02-20 デシフェラ・ファーマシューティカルズ,エルエルシー 胃腸間質腫瘍を治療するためのリプレチニブ
JP7677646B2 (ja) * 2019-12-10 2025-05-15 ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー 複製タンパク質a(rpa)-dna相互作用阻害剤
AU2020417282B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
SI4084778T1 (sl) 2019-12-30 2024-01-31 Deciphera Pharmaceuticals, Llc Formulacije inhibitorja amorfne kinaze in načini njihove uporabe
KR102195221B1 (ko) 2019-12-31 2020-12-24 서울대학교산학협력단 포스파티딜이노시톨 3-키나아제 억제제 및 프로그램화 세포 사멸 단백질 1 억제제를 포함하는, 삼중음성 유방암의 방사선 병용 치료용 약학적 조성물
CN111358952B (zh) * 2020-04-15 2022-03-15 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) 一种抗肿瘤药物组合物及其制剂和应用
IL312844A (en) * 2021-11-18 2024-07-01 Onconova Therapeutics Inc Methods and compositions for treating cancer
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019002B2 (en) 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
EP2280003B1 (en) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Process for preparing receptor-type kinase modulators
JP2007523151A (ja) 2004-02-18 2007-08-16 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 2−(ピリジン−3−イルアミノ)−ピリド[2,3−d]ピリミジン−7−オン
BRPI0510560A (pt) 2004-05-04 2007-11-20 Warner Lambert Co pirido[2,3-d] pirimidin-7-onas pirrolil substituìdas e seus derivados como agentes terapêuticos
WO2007004698A1 (ja) * 2005-07-06 2007-01-11 Sbc Corporation 漏洩電流検出装置及び漏洩電流検出方法
US8044062B2 (en) 2005-10-07 2011-10-25 Exelixis, Inc. Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha
ES2513165T3 (es) 2005-10-07 2014-10-24 Exelixis, Inc. Derivados de N-(3-amino-quinoxalin-2-il)-sulfonamida y su uso como inhibidores de la fosfatidilinositol-3-quinasa
US8247408B2 (en) * 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
JP2010500994A (ja) * 2006-08-16 2010-01-14 エグゼリクシス, インコーポレイテッド Pi3kおよびmekモジュレーターを使用する方法
GEP20115306B (enExample) * 2006-09-15 2011-10-10 Pfizer Prod Inc
UA100979C2 (ru) 2007-04-10 2013-02-25 Экселиксис, Инк. Применение пиридопиримидиноновых ингибиторов pi3k альфа для лечения рака
NZ579945A (en) 2007-04-11 2012-05-25 Exelixis Inc Pyrido [2,3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
NZ580009A (en) 2007-04-11 2012-06-29 Exelixis Inc Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
CA2683784A1 (en) 2007-04-11 2008-10-23 Exelixis, Inc. Pyrido[2,3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
AR073524A1 (es) 2008-09-30 2010-11-10 Exelixis Inc Piridopirimidinonas inhibidores de pi3k a y m tor

Similar Documents

Publication Publication Date Title
JP2010523670A5 (enExample)
HRP20131081T1 (hr) Kombinirane terapije koje sadrže hinoksalin inhibitor p13k-alfa za uporabu u lijeäśenju kancera
JP2016503799A5 (enExample)
JP2014034576A5 (enExample)
JP2021501208A5 (enExample)
JP2014508811A5 (enExample)
JP2015531747A5 (enExample)
AR080151A1 (es) Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia
JP2008535902A5 (enExample)
JP2009514870A5 (enExample)
JP2010241830A5 (enExample)
JP2011037841A5 (enExample)
JP2015508103A5 (enExample)
JP2013535491A5 (enExample)
JP2013537203A5 (enExample)
JP2013507448A5 (enExample)
JP2013516393A5 (enExample)
JP2017511321A5 (enExample)
JP2011506402A5 (enExample)
JP2017526662A5 (enExample)
JP2014530811A5 (enExample)
UA107675C2 (xx) Застосування n-(4-((3-(2-аміно-4-піримідиніл)-2-піридиніл)окси)феніл)-4-(4-метил-2-тієніл)-1-фталазинаміну для лікування раку, рефрактерного до лікування протираковим агентом
JP2015520770A5 (enExample)
JP2012512863A5 (enExample)
JP2014521609A5 (enExample)